HROW Stock Analysis: Harrow Health | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.138m USD | 12M Return: -27.8% | US4158581094 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.1M
Qual. Beats: 0
Rev. Trend: 98.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Harrow, Inc. (NASDAQ: HROW) is a U.S.-based eyecare pharmaceutical company headquartered in Nashville, Tennessee, that operates through two segments: Branded and ImprimisRx. The company develops and commercializes a broad portfolio of ophthalmic pharmaceutical products, including branded eye drops, steroid injections, and antifungals, as well as biosimilars such as BYOOVIZ (a LUCENTIS biosimilar) and OPUVIZ (an EYLEA biosimilar) used to treat conditions like wet age-related macular degeneration (AMD), macular edema, and diabetic retinopathy. Its ImprimisRx segment focuses on ophthalmology-specific compounded medications, while the Branded segment covers FDA-approved products like IHEEZO, VEVYE, ZERVIATE, VIGAMOX, and NATACYN. The company was founded in 1998 and was renamed from Harrow Health, Inc. to Harrow, Inc. in September 2023.
The ophthalmic pharmaceutical sector is a specialized niche within healthcare, addressing conditions such as cataracts, glaucoma, AMD, and inflammatory eye diseases, with demand driven by an aging population and rising prevalence of chronic eye disorders. Harrows hybrid business model, combining branded specialty drugs with a compounded pharmacy operation, allows it to serve multiple customer segments, including ophthalmologists, surgical centers, and patients requiring customized formulations.
- ImprimisRx segment revenue growth drives overall margin expansion
- IHEEZO and VEVYE branded launches accelerate top-line growth
- BYOOVIZ and OPUVIZ biosimilars pressure Lucentis and Eylea pricing
| Net Income: -28.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA 1.20 > 1.0 |
| NWC/Revenue: 48.51% < 20% (prev 44.87%; Δ 3.63% < -1%) |
| CFO/TA -0.04 > 3% & CFO -19.0m > Net Income -28.5m |
| Net Debt (225.5m) to EBITDA (22.1m): 10.20 < 3 |
| Current Ratio: 2.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (38.5m) vs 12m ago -0.88% < -2% |
| Gross Margin: 73.51% > 18% (prev 74.56%; Δ -1.05% > 0.5%) |
| Asset Turnover: 75.24% > 50% (prev 68.87%; Δ 6.37% > 0%) |
| Interest Coverage Ratio: -0.04 > 6 (EBIT TTM -1.03m / Interest Expense TTM 23.2m) |
| A: 0.33 (Total Current Assets 261.3m - Total Current Liabilities 114.2m) / Total Assets 443.0m |
| B: -0.43 (Retained Earnings -191.6m / Total Assets 443.0m) |
| C: -0.00 (EBIT TTM -1.03m / Avg Total Assets 403.0m) |
| D: 0.07 (Book Value of Equity 28.8m / Total Liabilities 414.2m) |
| Altman-Z'' = 0.82 = B |
| DSRI: 1.65 (Receivables 155.3m/77.8m, Revenue 303.3m/250.0m) |
| GMI: 1.01 (GM 74.56% / 73.51%) |
| AQI: 0.81 (AQ_t 0.39 / AQ_t-1 0.48) |
| SGI: 1.21 (Revenue 303.3m / 250.0m) |
| TATA: -0.02 (NI -28.5m - CFO -19.0m) / TA 443.0m) |
| Beneish M = -2.45 (Cap -4..+1) = BBB |
As of November 17, 2026, the stock is trading at USD 29.09 with a total of 474,146 shares traded. Over the past week, the price has changed by +5.90%, over one month by +6.63%, over three months by -26.31% and over the past year by -27.80%.
Current recommended Stop Loss: 26.00 (which is 10.6% or 1.7 ATR below the current price).
Harrow Health has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy HROW.
- StrongBuy: 9
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 62.6 | 115.3% |
P/E Forward = 38.0228
P/S = 3.7531
P/B = 67.5275
Revenue TTM = 303.3m USD
EBIT TTM = -1.03m USD
EBITDA TTM = 22.1m USD
Long Term Debt = 292.7m USD (from longTermDebt, last quarter)
Short Term Debt = 292.7m USD (from shortTermDebt, last quarter)
Debt = 300.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.14m
Net Debt = 225.5m USD (calculated: Debt 300.9m - CCE 75.3m)
Enterprise Value = 1.36b USD (1.14b + Debt 300.9m - CCE 75.3m)
Interest Coverage Ratio = -0.04 (Ebit TTM -1.03m / Interest Expense TTM 23.2m)
EV/FCF = -69.33x (Enterprise Value 1.36b / FCF TTM -19.7m)
FCF Yield = -1.44% (FCF TTM -19.7m / Enterprise Value 1.36b)
FCF Margin = -6.49% (FCF TTM -19.7m / Revenue TTM 303.3m)
Net Margin = -9.39% (Net Income TTM -28.5m / Revenue TTM 303.3m)
Gross Margin = 73.51% ((Revenue TTM 303.3m - Cost of Revenue TTM 80.3m) / Revenue TTM)
Gross Margin QoQ = 75.43% (prev 71.27%)
Tobins Q-Ratio = 3.08 (Enterprise Value 1.36b / Total Assets 443.0m)
Interest Expense / Debt = 7.70% (Interest Expense 23.2m / Debt 300.9m)
Taxrate = 5.47% (506k / 9.25m)
NOPAT = -976k (EBIT -1.03m * (1 - 5.47%)) [loss with tax shield]
Current Ratio = 2.29 (Total Current Assets 261.3m / Total Current Liabilities 114.2m)
Debt / Equity = 10.43 (Debt 300.9m / totalStockholderEquity, last quarter 28.8m)
Debt / EBITDA = 10.20 (Net Debt 225.5m / EBITDA 22.1m)
Debt / FCF = -11.47 (negative FCF - burning cash) (Net Debt 225.5m / FCF TTM -19.7m)
Total Stockholder Equity = 31.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.07% (Net Income -28.5m / Total Assets 443.0m)
RoE = -91.03% (Net Income TTM -28.5m / Total Stockholder Equity 31.3m)
RoCE = -0.32% (EBIT -1.03m / Capital Employed (Equity 31.3m + L.T.Debt 292.7m))
RoIC = -0.16% (negative operating profit) (NOPAT -976k / Invested Capital 606.4m)
WACC = 9.60% (E(1.14b)/V(1.44b) * Re(10.21%) + D(300.9m)/V(1.44b) * Rd(7.70%) * (1-Tc(0.05)))
Discount Rate = 10.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 65.87 | Cagr: 3.56%
[DCF] Fair Price = unknown (Cash Flow -19.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.04 | # QB: 0
Revenue Correlation: 98.07 | Revenue CAGR: 36.97% | SUE: 0.15 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.51 | Chg30d=-410.00% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=0.04 | Chg30d=-81.40% | Revisions=+0% | GrowthEPS=-80.1% | GrowthRev=+28.1%
EPS next Year (2027-12-31): EPS=2.66 | Chg30d=-3.94% | Revisions=+0% | GrowthEPS=+6558.3% | GrowthRev=+53.3%
[Analyst] Revisions Ratio: -25% (up=0, down=1)